Coronado nabs preclinical cancer assets from NeuPharma
This article was originally published in Scrip
After a restructuring of the company a little more than a year ago, Coronado Biosciences is continuing to add to its pipeline portfolio – the biotech struck a deal with NeuPharma on 19 March for an undisclosed number of preclinical cancer assets. Coronado agreed to pay an undisclosed up front fee, as well as development- and sales-based milestones. Coronado also agreed to single-digit sales royalties on any products that result. The biotech will develop and commercialize irreversible, third-generation epidermal growth factor receptor (EGRF) inhibitors worldwide, except for Asian countries. The deal comes about a year after Coronado's lead therapy – a treatment for Crohn's disease developed using parasitic worms – failed in Phase II trials to show any effectiveness beyond a placebo (scripintelligence.com, 14 October 2013). The clinical trial failure forced Coronado to pare down the company (scripintelligence.com, 08 November 2013).